Xeris Biopharma Holdings, Inc.
| Security | XERS / Xeris Biopharma Holdings, Inc. |
| Insider | Dawn Halkuff |
This page shows the track record and history of HALKUFF DAWN
insider trades in Xeris Biopharma Holdings, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.
It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean
it is illegal for them to make any
trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Dawn Halkuff in XERS / Xeris Biopharma Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Max |
Price at Max |
Max Profit ($) |
Max Return (%) |
|---|---|---|---|---|---|---|---|---|---|
| 2023-11-20 | 5,410 | 1.8400 | 5,410 | 1.8400 | 9,954 | 354 | 3.4700 | 8,819 | 88.59 |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Dawn Halkuff in XERS / Xeris Biopharma Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
|---|---|---|---|---|---|---|---|---|---|
| 2025-08-12 | 42,500 | 7.2759 | 42,500 | 7.2759 | 309,226 | 224 | 5.2900 | -84,400 | -27.29 |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Transaction History
| File Date |
Trade Date |
Form | Insider | Ticker | Security Title | Code | Direct | Exercise Price |
Unit Price |
Units Changed |
Value Changed (1K) |
Remaining Options |
Remaining Shares |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | 2026-06-04 | 4 | HALKUFF DAWN | XERS | Common Stock | D | 24,193 | 119,193 | ||||||
| 2026-06-05 | 2026-06-04 | 4 | HALKUFF DAWN | XERS | Common Stock | D | 6.0943 | -20,000 | -122 | 95,000 | ||||
| 2025-08-13 | 2025-08-12 | 4 | HALKUFF DAWN | XERS | Common Stock | D | 7.2759 | -42,500 | -309 | 115,000 | ||||
| 2025-06-04 | 2025-06-04 | 4 | HALKUFF DAWN | XERS | Common Stock | D | 50,000 | 157,500 | ||||||
| 2024-06-05 | 2024-06-05 | 4 | HALKUFF DAWN | XERS | Common Stock | D | 50,000 | 107,500 | ||||||
| 2023-11-21 | 2023-11-20 | 4 | HALKUFF DAWN By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017 | XERS | Common Stock | I | 1.8400 | 5,410 | 10 | 5,410 | ||||
| 2023-06-07 | 2023-06-07 | 4 | HALKUFF DAWN | XERS | Common Stock | D | 42,500 | 57,500 | ||||||
| 2022-06-09 | 2022-06-08 | 4 | HALKUFF DAWN | XERS | Common Stock | D | 15,000 | 15,000 | ||||||
| 2021-10-05 | 2021-10-05 | 4 | HALKUFF DAWN | XERS | Stock Option (Right to Buy) | D | 4.68 | 11,228 | 11,228 | |||||
| 2021-10-05 | 2021-10-05 | 4 | HALKUFF DAWN | XERS | Stock Option (Right to Buy) | D | 3.90 | 11,228 | 11,228 | |||||
| 2021-10-05 | 2021-10-05 | 4 | HALKUFF DAWN | XERS | Stock Option (Right to Buy) | D | 10.00 | 20,000 | 20,000 | |||||
| 2021-10-05 | 2021-10-05 | 4 | HALKUFF DAWN | XERS | Stock Option (Right to Buy) | D | 12.50 | 19,650 | 19,650 |
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)
